GlassScriptPhysician profile
Bhaskar Gundabolu
NPI 1346458767
$470,719.59
in general payments reported to CMS, 2019-2025
29 companies · $68.56 in 2025
The $68.56 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289K · 2020: $114K · 2021: $65K · 2022: $2,662 · 2023: $111 · 2024: $16.00 · 2025: $68.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $195.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $161,603.31 | 2019-2022 | |
| Amgen INC. | $125,163.50 | 2019-2025 | Evenity, Tepezza |
| Alexion Pharmaceuticals, INC. | $66,185.00 | 2019-2022 | |
| Novo Nordisk INC | $60,361.77 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $26,171.72 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $16,295.42 | 2019-2020 | |
| Abbott Laboratories | $10,046.27 | 2019-2023 | Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $3,834.36 | 2019 | |
| Dexcom, INC. | $237.23 | 2019-2025 | Dexcom G6 Transmitter |
| Medtronic Minimed, INC. | $164.85 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $79.08 | 2019 | |
| Sanofi-Aventis U.S. LLC | $71.45 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.32 | 2019 | |
| Shire North American Group INC | $60.69 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $48.60 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $47.18 | 2019 | |
| Mannkind Corporation | $44.57 | 2019-2020 | |
| Amarin Pharma, INC. | $39.95 | 2019 | |
| Valeritas, INC. | $29.42 | 2019 | |
| Insulet Corporation | $26.43 | 2019 | |
| Abbvie INC. | $24.77 | 2019 | |
| Pfizer INC. | $23.75 | 2019 | |
| Antares Pharma, INC. | $15.88 | 2019 | |
| Amneal Pharmaceuticals LLC | $15.33 | 2019 | |
| Beta Bionics, INC. | $14.53 | 2023 | Ilet Bionic Pancreas |
| Horizon Therapeutics Plc | $12.99 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.44 | 2019 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhaskar Gundabolu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.